Linvencorvir - Roche
Alternative Names: CpAM - Roche; RG-7907; RO-7049389Latest Information Update: 30 Aug 2024
Price :
$50 *
At a glance
- Originator Roche
- Class Antivirals; Small molecules
- Mechanism of Action Viral core protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 19 Jul 2024 Hoffmann-La Roche completes the Phase-II Piranga trial in Hepatitis B (Combination therapy, Treatment-experienced) in in the US, Bulgaria, Canada, Chile, China, France, Hong Kong, New Zealand, Romania, South Korea, Spain, Taiwan, Thailand and the UK (PO, Tablet) (NCT04225715) (EudraCT2019-002086-35)
- 10 Nov 2023 Efficacy data from a phase II trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)